Management of lipid disorders in patients living with HIV

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• HIV infection is now a chronic condition due to antiretroviral therapy (ART), leading to increased longevity and co-morbidities like cardiovascular disease (CVD).
• Dyslipidemia is a significant risk factor for CVD in the HIV-infected population, necessitating specialized management strategies.
• Current dyslipidemia management guidelines for HIV patients are primarily based on general population recommendations, highlighting a need for HIV-specific evidence.

Purpose of the Study:

• To provide a comprehensive guide for clinicians managing dyslipidemia in patients with HIV infection.
• To detail risk stratification, lipid therapy targets, and diagnostic/treatment approaches for HIV-associated dyslipidemia.
• To highlight knowledge gaps and areas for future research in managing dyslipidemia in this population.

Main Methods:

• Review of existing guidelines for dyslipidemia management in the general population.
• Synthesis of clinical and epidemiologic research findings specific to HIV-infected patients.
• Incorporation of authors' clinical experience in managing HIV-associated dyslipidemia.

Main Results:

• The review outlines background information on dyslipidemia, risk stratification, and lipid therapy targets.
• A step-by-step approach to diagnosing and treating dyslipidemia in HIV patients is presented, including specific drug information.
• Identified are management issues with limited or no specific information for the HIV population, indicating research gaps.

Conclusions:

• Managing dyslipidemia is crucial for the long-term health of HIV-infected individuals living with ART.
• Clinicians require tailored guidance for dyslipidemia management in HIV patients, integrating general guidelines with HIV-specific evidence.
• Further research is essential to address the numerous knowledge gaps in optimizing cardiovascular risk reduction for people with HIV.